Cyclin-dependent kinase 5 (CDK5), unlike other CDKs, is active only in neuronal cells where its neuronspecific activator p35 is present. However, it phosphorylates serines/threonines in S/TPXK/R-type motifs like other CDKs. The tail portion of neurofilament-H contains more than 50 KSP repeats, and CDK5 has been shown to phosphorylate S/T specifically only in KS/ TPXK motifs, indicating highly specific interactions in substrate recognition. CDKs have been shown to have a high preference for a basic residue (lysine or arginine) as the n؉3 residue, n being the location in the primary sequence of a phosphoacceptor serine or threonine. Because of the lack of a crystal structure of a CDK-substrate complex, the structural basis for this specific interaction is unknown. We have used site-directed mutagenesis ("charged to alanine") and molecular modeling techniques to probe the recognition interactions for substrate peptide (PKTPKKAKKL) derived from histone H1 docked in the active site of CDK5. The experimental data and computer simulations suggest that Asp 86 and Asp 91 are key residues that interact with the lysines at positions n؉2 and/or n؉3 of the substrates.
1 phosphorylate proline-directed serine and threonine residues in peptide/protein substrates. These kinases are active only when bound to their regulatory partners, cyclins. However, maximal kinase activation is achieved only after phosphorylation of these kinases by CDK-activating kinase (1 and references therein). CDK5 is slightly different from other CDKs; it is active only in neuronal cells because of the presence of its cyclin-like neuronal activator p35 and does not seem to require phosphorylation for its catalytic activity (1) (2) (3) . However, like other CDKs, it phosphorylates S/T in S/TPXK/R motifs unique to the CDK family of kinases (4, 5) . The specificity of this interaction is demonstrated by the phosphorylation of the tail portion of high molecular weight neurofilament-H (NF-H) by CDK5. The tail portion of this molecule contains 52 KSP repeats that can be classified as either KSPXK or KSPXXX. CDK5 specifically phosphorylates only KSPXK motifs and does not phosphorylate any other KSP site (4, 5) . Histone H1 is phosphorylated in vitro at a KTPKK motif (6) . These studies indicate that the CDKs have high affinity for a basic residue like lysine or arginine at the nϩ3 position of the sequence, where n is the position of the phosphoacceptor serine or threonine. The mechanism of activation of CDK2 by cyclin A was revealed by the crystal structures of CDK2 (7) and its complex with cyclin (8) . A recently published structure of a cyclin A-CDK2 complex phosphorylated by CDK-activating kinase demonstrated the structural basis for further activation by phosphorylation (9) . However, because of the lack of a crystal structure of a CDK-peptide substrate complex, the highly specific interactions addressed above are not well understood.
Alignment of more than 60 protein kinases (PKs) revealed the minimal catalytic domain to be ϳ 260 amino acids; this group exhibited 20 -60% sequence homology (10) . The crystal structures of the PKs solved to date reveal that the sequence homology and secondary structural elements are conserved at the functionally important sites, such as those involved in ATP binding and catalysis. When these amino acids are used to align the PKs, the major differences occur in the regions coding for loops (10) . Despite their homologous sequences and similar global structures, PKs differ surprisingly in the substrate sequences they recognize, indicating highly specific interactions between the active sites of the enzyme and the substrates.
cAMP-dependent protein kinase (PKA) was the first kinase to be crystallized without (11) and with (12) a RRXS/A pseudo substrate peptide (PKI). Consequently, the crystal structure of the PKA⅐PKI complex has been used as a model kinase-substrate system. The recently published structure of phosphorylase kinase with a peptide substrate further confirms the specificity of these interactions (13) . These structures reveal a highly specific network of interactions between the charged residues in the substrate with their oppositely charged partners in the enzyme. The differences in amino acid composition in the catalytic clefts of PKs account for differences in substrate specificity for these kinases (14, 15) .
To understand the key interactions involved in this highly specific enzyme-substrate interaction, we have used site-directed mutagenesis, reaction kinetics, and molecular modeling. We constructed a homology model of CDK5 using the CDK2 coordinates from the cyclin-CDK2 crystal structure (9) and docked a peptide derived from histone H1, which is an in vitro substrate for CDK5 and other CDKs (6) . Site-directed mutagenesis was used to confirm the interactions suggested by the computer modeling. Further refinement of the model included inter-residue restraints suggested by the enzyme kinetics measurements of the designed CDK5 mutants.
EXPERIMENTAL PROCEDURES
All fine chemicals were purchased from Sigma. The peptide substrates were synthesized by either Research Genetics or QCB Chemi-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
cals. [␥-
32 P]ATP was purchased from NEN Life Science Products.
Expression and Purification of Proteins-GST-CDK5 in pGEX 2TK
was constructed by putting the BamHI fragment of His-tag CDK5 (3) into BamHI-cut pGEX 2TK. GST-p25 in pGEX 4T-2 was constructed by a polymerase chain reaction method using the oligonucleotides 5Ј-GTC-CGGATCCGCCCAGCCCCCGCCG-3Ј as a forward primer, 5Ј-GTGAT-GAATTCTGGATCACCGATC-3Ј as a reverse primer, and DNA from the His-tag p35 construct as a template (3). The polymerase chain reaction products were digested with BamHI and EcoRI, and the resulting fragments were cloned into BamHI-EcoRI-cut pGEX 4T-2. The proteins were expressed as described earlier (4, 5) . Purification of GST fusion proteins was carried out using glutathione-agarose chromatography by standard procedures (Amersham Pharmacia Biotech) and as described earlier (5) . The purity of the proteins was assessed by SDS-polyacrylamide gel electrophoresis and Coomassie Blue staining of the gels. The protein concentration was estimated by densitometric analysis of these gels.
Site-directed Mutagenesis-The "charged to alanine" mutations were made using a commercial kit (Quick Change TM , Stratagene). In brief, a pair of complementary primers of 30 -40 bases was designed with desired mutations placed in the middle of the sequence. Parental cDNA inserted in pGEX 2TK was amplified using Pfu DNA polymerase with these primers for 15 cycles in a DNA thermal cycler (Perkin-Elmer). After digestion of the parental DNA with DpnI, the mutants were transformed into Escherichia coli (DH5␣ strain, Life Technologies, Inc.). The mutations were confirmed by DNA sequencing. The GST fusion mutant proteins were expressed and purified as described above.
Phosphorylation Assay and Enzyme Kinetics-Standard assay mixtures contained 50 mM Tris, pH 7.4, 2.5 mM MgCl 2 , 1 mM EGTA, 150 -165 ng of wild-type CDK5 or different mutants complexed with a molar excess of p25 (preincubated enzyme preparation), 100 M [␥-32 P]ATP, and 0.1-10 mM peptide substrate in a total volume of 30 l. Reactions were initiated by adding [␥- 32 P]ATP and were carried out at 30°C for 60 -80 min. Under these conditions, the rate of phosphorylation was constant for more than 2 h and proportional to the amount of enzyme. Reactions were terminated by adsorption of the assay mixture on phosphocellulose paper P81(Whatman). Phosphopeptide formation was measured by counting the radiolabeled 32 P incorporation after several washings of the phosphocellulose paper with 75 mM phosphoric acid. Kinetic constants were derived by fitting the Michaelis-Menten equation to the data using the Kaleidagraph program. Each experiment was done at least twice. Representative kinetic constants are shown in Tables I and II , and the variation in these constants from one experiment to another was typically 10 -15%. The apparent peptide affinities are compared on the basis of the K m and V max /K m values.
Molecular Modeling-Using the program LOOK (16), CDK5 was aligned to CDK2 (9) , and a model of CDK5 was built exploiting its high homology to CDK2 (62% identity). Atoms of CDK5 were assigned coordinates using the SegMod algorithm (16) . An ATP molecule and magnesium were docked to CDK5 by copying the corresponding coordinates from the CDK2 complex.
The CDK5 model was then superimposed on the crystal structure of PKA (pdb file 2CPK) by best-fitting only the backbone (N, C␣, C) atoms in the 13-residue "catalytic loops." Of particular interest was the close proximity (1.0 Å separating C␣ atoms) of Asp 86 in CDK5 to Glu 127 of PKA. The Glu 127 of PKA forms a salt bridge with Arg 18 of PKI (2cpk), and Arg 18 of PKI corresponds to Lys 6 of the H1 peptide in the antiparallel alignment (Fig. 1B) . This structural alignment and subsequent modeling of CDK5 complexed with the H1 peptide were performed with the program CHARMM (17) and an all-atom parameter set (18, 19) running on Hewlett-Packard workstations.
In modeling the CDK5⅐H1⅐peptide complex, several approximations were employed. A distance-dependent dielectric (⑀ ϭ r) coefficient was used to screen electrostatic interactions with a potential energy "shifted" to zero at 12 Å. The shifted potential monotonically damps the electrostatic forces for this dielectric model (20) . The distance-dependent dielectric is a rather crude approximation to an implicit solvent, but it maintains reasonable hydrogen bond distances.
Entropic effects were ignored, and a limited (non-ergodic) search of conformations was performed. In other words, we did not attempt to solve the ab initio docking problem, which would require a more accurate energy function and more exhaustive conformational sampling. Rather, the goal of the modeling was to aid in the choice and interpretation of experiments. Although our electrostatic approximations overly stabilize salt bridges, our intent was to enforce these interactions, not to predict them from first principles. The details of the peptide backbone conformation and side chain packing should not be overinterpreted, but our model can be used to test "lower resolution" hypotheses. For example, we can predict whether the H1 peptide is long enough and flexible enough to interact simultaneously with the ATP and a specific subset of CDK5 residues. Thus, prospective interactions between CDK5 and the peptides identified in early stages of the modeling led us to perform specific mutation experiments. Similarly, the measured enzyme kinetics were incorporated into later stages of modeling through the addition of inter-residue distance restraints favoring specific salt bridges between CDK5 and the H1 peptide. Multiple families of short Monte Carlo (MC) simulations were run in succession, differing in the moves attempted and the restraints employed. In the latter stages of the modeling, protein residues near the peptide were free to move, but in each MC simulation the CDK5 molecule was held fixed while random rigid body translations and rotations of the entire H1 peptide were explored as well as random rotations of the peptide dihedral angles. Configurations were energy minimized somewhat to relieve bad contacts before applying the Metropolis criterion (21) for accepting conformations at a temperature of 600 K. A subset of torsions was included in the MC move set, but all peptide degrees of freedom were allowed to relax upon minimization. Positional restraints were used to guide the docking of the H1 peptide in a configuration antiparallel to that of PKI binding to PKA. Again, this configuration was investigated because it allows interaction between Asp 86 of CDK5 and Lys 6 of the peptide. In each MC simulation, a restraint was used to keep the gamma oxygen of the peptide Thr 3 close to the third phosphate group of the ATP molecule.
H1 Peptide Docked in the Antiparallel Orientation-The goal of the first family of MC simulations was to dock only the first several residues of the H1 peptide. 100 runs were started with the peptide in an extended conformation near the ATP molecule. Inter-residue distance restraints were used to favor energetically four interactions between a CDK5 residue and a peptide residue: Asp 86 Only the 11 and angles not involving the first four residues of the peptide were moved by the MC procedure.
Next, MC simulations were performed with both backbone and side chain dihedral angles included in the move set, but the fixed CDK5 molecule resulted in the acceptance of very few moves. Therefore, the protein was made increasingly flexible in the neighborhood of the peptide as follows. First, simulated annealing was employed during which the peptide and all atoms within 5 Å of it were free to move. The system was heated to 600 K in 20 ps and cooled to 100 K over 230 ps and energy minimized. Next, 100 ps of molecular dynamics at 300 K was simulated during which all residues with any atom within 5 Å of the peptide were in motion. The 100 structures saved (1/ps) were energy minimized to a root mean square gradient of 0.01 kcal/mol/Å. Finally, all residues in the lowest energy structure with any atom within 10 Å of the peptide were freed of constraints and energy minimized to a root mean square gradient of 0.001 kcal/mol/Å. The resulting structure is depicted in Fig. 2 .
H1 Peptide Docked in the Parallel Orientation-Docking of the H1 peptide in an orientation parallel to that of PKI relative to PKA was also investigated (Fig. 1B) (9) .
RESULTS
Homology Model of CDK5-It is well known that CDKs are not active on their own; they require binding to regulatory cyclins to be activated (1). However, maximal activation is achieved after phosphorylation at Thr/Ser in the T-loop of most CDKs. In the case of CDK2, it is Thr 160 in the cyclin A-CDK2 complex. This complex has been crystallized in both phosphorylated (9) and unphosphorylated (8) forms. These crystal structures help elucidate the mechanism of activation of CDKs. Briefly, the binding of cyclin A to CDK2 causes the T-loop (146 -166) to move 21 Å from its position in the CDK2 structure, thereby opening the catalytic cleft, allowing access to the substrate, and orienting ATP in a position that favors phosphotransfer (8, 9). The main regulator of CDK5 is a neuron-specific protein p35 or its truncated form p25 (2, 3), accounting for the activity of this enzyme mainly in neurons. p35 does not have any sequence similarity to cyclins. Sequence homology among cyclins is rare; even two structurally similar cyclin motifs typically have very different sequences (22, 23) . Recent studies by two groups have suggested that p35 consists of a cyclin-like fold (24, 25) ; however, unlike the regulators of other CDKs, p35 seems to achieve maximal activation of CDK5. Other CDKs seem to be catalytically active only upon phosphorylation in the T-loop subsequent to cyclin binding (1, 2) . A recent crystal structure of cyclin A-CDK2 in this phosphorylated state has revealed that the T-loop moves further away from the catalytic cleft upon phosphorylation at Thr 160 in the T-loop (9) . There seems to be no difference in substrate specificity caused by this effect; it only increases the rate of phosphorylation. Therefore, we assume that the active conformation of CDK5 is similar to that of CDK2 in the cyclin A-CDK2 (phosphorylated) complex (9) . Thus, we modeled CDK5 in its active form using coordinates from the cyclin A-CDK2 (1jst.pdb) complex using the program LOOK (as described under "Experimental Procedures") taking advantage of the 62% sequence identity and a high sequence homology between these two kinases (Fig. 1A) . The CDK5 model exhibits a bilobal structure (Fig. 2) , a conformation representative of protein kinases. The small lobe is rich in ␤-sheets and contains the glycine-rich motif important for ATP binding. The ATP binding site is common to the entire PK family.
The N-lobe of CDK5 also contains the PSSALRE helix, which corresponds to the PSTAIRE helix in CDK2. This helix is another feature found in all CDKs and is important for interaction with cyclins. The PSTAIRE helix rotates by several Å into the catalytic cleft (7-9) upon cyclin A binding to CDK2. and Glu 51 is broken (3). The bigger C-lobe is predominantly helical but contains loops that are important for interaction with suc family proteins (26) and also the T-loop, which is important for the kinase activity as described above. The catalytic site of the enzyme lies between the two lobes, enabling the ATP to transfer phosphate to Ser/Thr residues of the peptide substrate. The residues important for substrate binding have not been identified; but based on the PKA⅐PKI structure, some residues in the C-lobe have been suggested in substrate binding (9) .
Peptides Bound to the Active Site of CDK5-Both of the peptides studied here (H1 and NF-H, Table I ) contain at least one S/TPXK motif, which is a consensus sequence for CDK family kinases. The H1 peptide used for docking was derived from histone H1 and contains the TPKK motif, which is the in vitro site phosphorylated by CDK5 in histone H1 (6) . It is possible that this peptide has a higher affinity because of the presence of 5 lysines (out of 10 residues) that interact with acidic residues in the catalytic cleft and with the ATP. We also used an NF-H-derived peptide for our enzyme kinetics studies with different mutants because NF-H is phosphorylated at similar SPXK motifs by CDKs. We showed recently that CDK5 has a higher affinity for the first KSPXK repeat (X ϭ A) than for the second repeat (X ϭ E) (5), consistent with the work of Beaudette et al. (6) , who showed that CDK5 prefers X ϭ K or R over X ϭ neutral amino acid. When X ϭD or E, the peptides make very poor substrates.
It is likely that the substrate in CDK5 or other CDKs binds to a site analogous to that observed in the PKA⅐PKI complex (12) because CDKs and PKA have similar overall structures and almost superimposable catalytic clefts that include the glycine-rich ATP binding domains and the catalytic base, Lys 33 . When the peptide substrate sequences are aligned with the PKI sequence in a parallel (conventional) fashion with the Ser/Thr matching the corresponding residue in PKI, none of the lysines of the CDK5 substrate peptides corresponds to any arginine of PKI (Fig. 1B) . However, if the substrate sequences are aligned with PKI in an antiparallel fashion, the nϩ3 lysine of either NF or H1 peptide aligns with the nϪ3 arginine in the RRXS motif of PKI. For the H1 peptide, two other lysines align with PKI arginines in the antiparallel alignment (Fig. 1B) .
Effect of Site-directed Mutagenesis of Residues Implicated in Substrate
Recognition-Charged to alanine scanning mutagenesis of CDK5, combined with kinetic analyses of the mutant enzymes, was used to investigate interactions involving acidic residues near the ATP binding pocket in our homology model of CDK5. As described above, Asp 86 and Asp 91 were implicated in binding to the peptide substrates. Independent mutation of these residues to alanine caused a 2-fold decrease in apparent affinity for the NF peptide (Table I) . However, there was no significant difference measured in the K m for ATP binding to the D86A (K m ϭ 140 M) and D91A (K m ϭ 210 M) mutants compared with CDK5 (K m ϭ 160 M).
For the higher affinity H1 substrate, the decrease in apparent affinity was 5-fold for both CDK5 mutants ( Table I ). Assuming that the Asp to Ala mutations do not greatly affect the structure of CDK5, it would appear that both Asp 86 and Asp 91 form stabilizing interactions with both peptides, arguably salt bridges to one or more lysines. To identify the alleged salt bridge interactions between CDK5 and the H1 substrate, the D86A and D91A mutants were subjected to kinetic analyses with Ala-substituted H1 peptides in which either the nϩ2 or nϩ3 residue (Lys 5 or Lys 6 ) was replaced by alanine (Table II) . We report V max /K m in Table II to represent the catalytic efficiency of the enzyme. Because, in general V max /K m decreases as K m increases, we interpret our results in terms of K m , which reflects apparent binding affinity.
In H1 peptide binding to wild-type CDK5, the nϩ2 alanine substitution increased K m by a factor of 5, whereas the nϩ3 alanine substitution increased K m by a factor of 7 (Table II) . These results are in agreement with reports that the presence of non-basic residues in the nϩ2 or nϩ3 position makes for a very poor substrate for CDKs (6, 14) .
The K m values for H1 peptide binding to CDK5 and to the D86A mutant differ by a factor of 5. For the nϩ2 alanine peptide, these K m values differ by a factor of only 1.5. Thus, the nϩ2 alanine peptide is considerably less sensitive to changes in Asp 86 than is the H1 peptide, suggesting that Lys 5 of H1 probably interacts with Asp 86 of CDK5. The weakening of the Lys 5 -Asp 86 interaction was essentially independent of whether it was Lys 5 or Asp 86 (factor of 5) that was replaced by Ala (Table II) .
For the nϩ3 alanine peptide, the K m values for binding to CDK5 and to D86A differ by a factor of 2.5 compared with the factor of 5 for the H1 peptide. The effects observed for Lys 6 (nϩ3) are less dramatic than those discussed above for Lys 5 (nϩ2). Still, the data suggest that Lys 6 also interacts with Asp 86 . The proximity of Lys 6 to Lys 5 certainly makes this conclusion plausible.
When Asp 91 was mutated to Ala, the reduction in apparent H1 affinity was comparable to that resulting from the D86A mutation, implicating Asp 91 as another residue that interacts favorably with H1. D91A binds both the nϩ2 alanine and nϩ3 alanine peptides very poorly compared with wild type, suggesting that a second interaction has been weakened, i.e. that Asp 91 interacts with an H1 residue other than Lys 5 or Lys 6 . The data in Table II with the peptide was studied using a CDK5 double mutant (D86A/D91A). Relative to wild-type CDK5, this mutant showed an ϳ18 fold decrease in apparent affinity (K m ϭ 0.7 mM) for the H1 peptide, and relative to either D86A or D91A, it showed a 3.5-fold decrease. These results are further evidence that these residues are important for peptide binding. The modeled complex (Fig. 3) 9 , we measured enzyme kinetics with two additional Alasubstituted H1 peptides, nϩ5 alanine and nϩ6 alanine. The results indicate no increase in K m for the binding of these peptides to D91A (Table II) . In comparison, the binding to wild-type CDK5 and D86A showed a 3-5-fold and 2-fold increase in K m , respectively. Taken together, the kinetic data for the nϩ5 alanine and nϩ6 alanine peptides support the possibility of interactions between Lys 8 and Lys 9 of the H1 peptide and Asp 91 of CDK5, as was suggested originally by the molecular modeling.
In the model of the H1 peptide bound to CDK5 (Fig. 3) , each of the peptide's five lysines interacts with one or more negatively charged groups. Additional salt bridges identified in the model involve the ATP, Asp 143 , and Lys 88 (Table III) .
Effect of Mutation of Residues Implicated in Substrate Binding in the Parallel
Orientation-The crystal structure of the PKA⅐PKI complex can serve as a template for substrate binding. We modeled the H1 substrate peptide in an orientation comparable to that of PKI bound to PKA (Fig. 1B) with a distance restraint that kept the phosphoacceptor threonine within hydrogen bonding distance of the ATP. It appeared from the modeling (not shown) that the only likely salt bridge partners for Lys 5 (Fig. 2) . We mutated each of these six residues (except Asp 208 ) to Ala. The D143A and E160A mutants were not active. None of the other three Asp 3 Ala mutations resulted in a significantly altered K m value for H1 peptide (Table I) . These data strongly support the conclusions based on the D86A and D91A data, namely that the peptide substrate binds in the antiparallel orientation.
DISCUSSION
There is no available crystal structure of a CDK-substrate complex. Thus, the mechanism of this interaction is unknown. Because of the very high specificity of CDKs for the S/TPXK motifs, it is important to probe the mode of binding of these substrates. Although unambiguous interpretation of mutagenesis experiments is difficult, we assume that non-local conformational changes induced by mutations and many-body interactions can be neglected to a first approximation. We therefore interpret our mutagenesis data in terms of pairwise interactions, specifically salt bridges between CDK5 and the peptide substrates.
Based on the crystal structure of the PKA⅐PKI complex, it has been speculated that some of the acidic residues (e.g. Glu 160 , Glu 206 , Glu 209 ) in the C-lobe of CDKs might interact with the essential lysines of the peptide substrate (9 (Fig. 2A) . The consensus sequence for PKA is RRXS/A. Therefore, Lys 5 and Lys 6 of the CDK5 substrates align well with the nϪ2 and nϪ3 arginines in an antiparallel alignment (Fig. 1B) . Furthermore, Lys 9 of the H1 peptide corresponds to the nϪ6 arginine.
The parallel alignment of H1 peptide to PKI is not as compelling because no lysines line up with the arginines of PKI (Fig. 1B) . Preliminary docking of the peptide in this parallel orientation suggested the possibility of salt bridges involving residues Asp 143 , Asp 206 , Asp 208 , Asp 209 , Asp 234 , and Glu 160 . These acidic residues have been considered important in substrate binding by other reports (9) . We mutated each of them (except Asp 208 ) to Ala. There was no significant change in K m values for peptide interaction with these mutants except for D143A and E160A. For these mutants, there was no kinase activity, and determining the apparent peptide affinity was not possible. Along with Lys 33 , Asp 143 orients the ATP in a conformation that facilitates phosphotransfer (7) (8) (9) . It is thus not surprising that the D143A mutant is inactive. Glu 160 is part of the flexible T-loop, and it may be that the conformation of CDK5 is especially sensitive to mutations in this region (Fig. 2) .
The pairwise combinations of the D86A and D91A mutants (each defective in substrate binding) with Ala-substituted peptides suggest that nϩ2 and nϩ3 lysines interact with Asp 86 in is within reach of Lys 8 and Lys 9 when the N 2 -terminal half of the peptide is docked to the ATP. Although these lysines are not part of the TPKK consensus CDK motif, the D91A mutant data suggest that a stabilizing interaction outside the TPKK region is present in the native system. Interestingly, in the case of other major proline-directed kinases, extracellular signalregulated kinases (ERKs), the residue corresponding to Asp 91 is a neutral residue (Fig. 1A) . These kinases do not have any known preferences for charged residues following the proline (15) . Recently, it was shown that the NF peptide and other related peptides containing nϩ3 as basic residues were very poorly recognized by ERKs (27) compared with the peptides with nϩ3 as nonbasic residues. A proline at the nϩ1 position is a common essential feature in substrates for both CDKs and ERKs. These kinases do not phosphorylate substrates without proline. It is possible that orientation of the serine hydroxyls for hydrogen bonding with ATP requires proline at the nϩ1 position. CDKs seem to require additional interactions with the (Table II) . However, when both of these lysines are replaced by a neutral or acidic residue, the peptide is not phosphorylated by CDK5 (27) . Our data and model also suggest additional stabilization of the complex by salt bridges involving Lys 8 and Lys 9 of the substrate and Asp 91 of CDK5. PKA and phosphorylase kinase have been the only two serine/threonine kinases to be crystallized as ternary complexes with ATP and their peptide substrates (12, 13) . These two kinases show a high degree of structural similarity in their ternary complexes. Because the cyclin A-CDK2 (phosphorylated) crystal structure differs from PKA and phosphorylase kinase in several ways, it has been speculated that CDKs might have a different catalytic mechanism (10) . A recently reported crystal structure of CDK2 complexed with staurosporine, an inhibitor of CDKs and other protein kinases, which binds at the ATP binding pocket, revealed that staurosporine interacts with Asp 86 (28) . This interaction suggested that the peptide substrate binding site of CDKs is very close to the ATP pocket, consistent with our observation that mutation of Asp 86 results in a decreased apparent affinity for the peptide. Also, recent work in our laboratory has shown that a pseudo substrate analogue of the NF peptide was surprisingly competitive with ATP. 2 Given the close proximity of the ATP and peptide binding sites, peptide binding at or near Asp 86 could affect ATP binding. Interestingly, in the same study we showed that peptide binding promoted ATP binding. 2 Taken together, these data suggest that a conformational change resulting from peptide binding could trigger events important for catalysis.
Because of the lack of a crystal structure of a CDK-substrate complex, the peptide substrate binding site has not been identified. Therefore, design of specific inhibitors for CDK family kinases has not been possible. Most of the available inhibitors bind in the ATP pocket, which makes them less specific since the ATP pockets of most PKs are structurally very similar. But in the case of CDKs, the interactions with the substrate are very specific; CDKs specifically target SPXK-type motifs. The enzyme kinetics and molecular modeling reported here indicate that the H1 peptide most likely binds to CDK5 in an orientation that is antiparallel to that of PKI bound to PKA. The binding site implicated by this study should help guide the design of specific inhibitors for CDKs.
